Haemonetics’ Acquisition of Cardiva Medical

February 2, 2021
FORWARD LOOKING STATEMENTS

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this presentation may include, without limitation, plans and objectives of management for the operation of Haemonetics Corporation (the “Company”), statements regarding the timing of completion of the acquisition of Cardiva Medical, Inc. (“Cardiva”) and the consummation of such acquisition, the anticipated financing of the acquisition, the anticipated benefits to the Company arising from the completion of the acquisition, the impact of the acquisition on the Company’s business strategy and future business and operational performance, and the assumptions underlying or relating to any such statement. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the failure to realize the anticipated benefits of the acquisition or the acquisition, its announcement or pendency having an unanticipated impact, the Company’s ability to predict accurately the demand for products and products under development by it and Cardiva and to develop strategies to successfully address relevant markets, the impact of competitive products and pricing, technical innovations that could render products marketed or under development by the Company or Cardiva obsolete, risks related to the use and protection of intellectual property, the risk that the transaction may not be completed in a timely manner or at all, and the risk that using debt to finance, in part, the acquisition will substantially increase the Company’s indebtedness. These and other factors are identified and described in more detail in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”). Haemonetics does not undertake to update these forward-looking statements.

MANAGEMENT’S USE OF NON-GAAP MEASURES

This presentation contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets, and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP.
## Haemonetics to acquire Cardiva Medical

### Cardiva Medical Overview
- Leading vascular closure device company
  - VASCADE MVP product used for electrophysiology procedures (e.g., cardiac ablation)
  - VASCADE product used for coronary & peripheral procedures (e.g., percutaneous coronary intervention)
- Privately held company headquartered in Santa Clara, CA (founded in 2002)

### Deal Terms
- Total purchase price of up to $510M cash
  - $475M in upfront cash payable at closing and up to $35M in contingent consideration based on sales growth
  - Financed through cash, existing revolving credit facility, and an additional $150M term loan
- Acquisition expected to close in first quarter of calendar 2021, subject to customary conditions

### Shareholder Value
- Projected to deliver ROIC of 10% by year 5
  - Expected to be immediately accretive to top-line growth, gross margins and adjusted gross margins
  - $65-$75M in anticipated net sales in FY22 (+40% YoY growth)
- Estimated dilutive impact on adjusted EPS of ($0.15-$0.20) in FY22, about neutral in FY23

---

1 A reconciliation of the estimated impact on adjusted net earnings per diluted share ("Adjusted EPS"), a non-GAAP measure, to its most comparable GAAP measure is available at the end of the Company’s January 20, 2021 press release announcing the pending Cardiva acquisition, a copy of which is available on the investor relations page of the Company’s website at [www.haemonetics.com](http://www.haemonetics.com).
Cardiva Medical product platform includes differentiated products with strong clinical evidence

**Extravascular Design**
- No permanent or intraluminal implants

**Simple and Easy to Use**
- Single operator
- No sutures, no materials

**Bioabsorbable and Thrombogenic Collagen Plug**
- Expands to fill tissue tract

**VASCADE**
Coronary and Peripheral Procedures
Only marketed technology clinically proven to reduce access site complications
- RESPECT trial vs manual compression
  - Statistical superiority on reduced bleeding complications
  - Significant reduction in time to hemostasis and ambulation

**VASCADE MVP**
Electrophysiology Procedures
Only marketed technology clinically proven and labeled for EP procedures
- AMBULATE trial vs manual compression
  - Reduce time to ambulate by 3.9 hours
  - 58% reduction in opioid use
  - Significant improvement in patient satisfaction

---

© 2021 Haemonetics Corporation
Cardiva Medical is growth accretive and aligned with HAE’s Corporate Strategy

**Winning Markets**
- **ELECTROPHYSIOLOGY PROCEDURES**
  ~$330M U.S. market¹
growing rapidly

**Leading Position**
- **CORONARY & PERIPHERAL PROCEDURES**
  ~$1.1B U.S. market¹

**Superior Results**
- Immediately accretive to revenue growth and adjusted gross margins
- Leverage HAE’s G&A infrastructure to accelerate profitability
- Expand VASCADE reach through HAE’s global commercial capabilities
- Opportunity for call point expansion for Hemostasis Management

¹ 2019 projected Total Addressable Market based on 2019 Decision Resource Group reported procedures, Company reported percutaneous access sites per procedure, and Company ASPs.
² Compared to manual compression